$BHC
Bausch Health Companies Inc. · NYSE · Healthcare
- Market cap
- 2.41B
- Volume
- 2.40M
- P/E
- 1.50
- Day range
- 6.20 – 6.49
- 52w range
- 4.33 – 8.00
- Analyst target
- 7.50
AI Summary
Generating a unique summary for BHC…
AI-generated for information only — not investment advice.
Share this ticker
$BHC -0.77% at 6.44 Stanley Druckenmiller and 3 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/BHC
Company summary
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Institutional ownership
Institutions hold 65.00% · insiders 11.12% · 314 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| PAULSON & CO. INC. | 73.26M | $471.77M | 19.57% | 2026-06-30 |
| Goldentree Asset Management LP | 34.67M | $223.25M | 9.26% | 2026-06-30 |
| Royal Bank of Canada | 10.83M | $69.76M | 2.89% | 2026-06-30 |
| Healthcare of Ontario Pension Plan Trust Fund | 8.00M | $51.52M | 2.14% | 2026-06-30 |
| Vanguard Capital Management LLC | 7.47M | $48.08M | 1.99% | 2026-06-30 |
| Goldman Sachs Group Inc | 6.23M | $40.09M | 1.66% | 2026-06-30 |
| MFN Partners Management, LP | 6.00M | $38.64M | 1.60% | 2026-06-30 |
| SG Americas Securities, LLC | 5.54M | $35.65M | 1.48% | 2026-06-30 |
| Acadian Asset Management. LLC | 5.48M | $35.31M | 1.46% | 2026-06-30 |
| Kohlberg Kravis Roberts & Co. L.P. | 5.24M | $33.71M | 1.40% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| LEUNG SANDRA | Director | Stock Award(Grant) at price 5.83 per share. | 5.8K | 2026-09-30 |
| WECHSLER AMY B | Director | Stock Award(Grant) at price 5.83 per share. | 1.2K | 2026-09-30 |
| PAULSON JOHN A. | Director | Stock Award(Grant) at price 5.83 per share. | 10.7K | 2026-09-30 |
| LENAR AIMEE J | Officer | Sale at price 7.03 per share. | 36.8K | 2026-08-19 |
| LEUNG SANDRA | Director | Stock Award(Grant) at price 4.93 per share. | 6.8K | 2026-06-30 |
| PAULSON JOHN A. | Director | Stock Award(Grant) at price 4.93 per share. | 12.7K | 2026-06-30 |
| LEUNG SANDRA | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| KAVANAGH SARAH BALDWIN | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| POWER ROBERT N | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| GARCIA CHRISTIAN A | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| WECHSLER AMY B | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
| PAULSON JOHN A. | Director | Stock Award(Grant) at price 0.00 per share. | 45.9K | 2026-05-22 |
Analyst ratings
Consensus score 3.00 (1 = strong buy, 5 = sell) · mean target 7.50
- RBC CapitalSector Performmain2026-04-27
- BarclaysEqual-Weightmain2026-02-25
- Truist SecuritiesHoldmain2026-01-07
- BarclaysEqual-Weightinit2025-12-09
- RBC CapitalSector Performmain2025-05-02
- JefferiesHolddown2025-02-06
- RBC CapitalSector Performmain2025-01-30
- RBC CapitalSector Performmain2024-11-01
- RBC CapitalSector Performmain2024-08-02
- Piper SandlerUnderweightdown2024-08-02
Earnings
Next report: 2026-10-28
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 3Q2025 | 1.16 | 1.06 | 0.11 |
| 4Q2025 | 1.10 | 1.26 | -0.16 |
| 1Q2026 | 0.78 | 0.69 | 0.09 |
| 2Q2026 | 1.26 | 1.01 | 0.25 |
SEC filings
- 10-QPeriodic Financial Reports2026-07-30Open
- 8-KCorporate Changes & Voting Matters2026-07-29Open
- 8-KCorporate Changes & Voting Matters2026-07-01Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-06-01Open
- 8-KCorporate Changes & Voting Matters2026-05-19Open
- 10-QPeriodic Financial Reports2026-04-30Open
- 8-KCorporate Changes & Voting Matters2026-04-29Open
- DEFA14AProxy Statements2026-04-08Open
- 8-KCorporate Changes & Voting Matters2026-03-02Open
- 10-KPeriodic Financial Reports2026-02-19Open
Latest BHC news
- Bausch Health Canada Announces Expanded Public Reimbursement for (Pr)OKEDI® (Risperidone for Extended-Release Injectable Suspension) Across Canada for the Treatment of Schizophrenia
Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), today announced expanded public reimbursement for PrOKEDI® (extended-release injectable suspension of risperidone) 75 mg and 100 mg, with coverage now available for eligible patients, subject to the applicable reimbursement criteria, through public drug plans in seven provinces and multiple federal drug plans.
Mon, 19 Oct 2026 12:00:00 +0000
- Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduat
Mon, 12 Oct 2026 12:00:00 +0000
- Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.
Tue, 06 Oct 2026 11:00:00 +0000
- Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
BHC, CDNA, DOLE and CHEF offer defensive exposure as consumer confidence falls amid inflation and geopolitical tensions.
Wed, 30 Sep 2026 11:29:00 +0000
- Best Value Stocks to Buy for September 22nd
BHC, OPHC and TRVG made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 22nd, 2026.
Tue, 22 Sep 2026 09:20:00 +0000
- Bausch Health (BHC) Expands Probiotic Skincare Bet To Six New Markets
On September 8, Bausch Health Companies Inc. (NYSE:BHC) and Belgian skincare innovator YUN announced they are extending their microbiome-focused dermatology partnership into Mexico and five additional markets spanning Central and Eastern Europe and Central Asia. The move builds on a 2025 launch in Poland and lands just weeks after the company raised its full-year guidance […]
Wed, 16 Sep 2026 04:34:07 +0000
- Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA markets following the 2025 launch in Poland.
Tue, 08 Sep 2026 12:00:00 +0000
- Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning September 1, 2026.
Tue, 01 Sep 2026 12:01:00 +0000